You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Tumor‐associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation
|
|---|---|
| Published in |
International Journal of Cancer, March 2018
|
| DOI | 10.1002/ijc.31335 |
| Pubmed ID | |
| Authors |
Rudolf Kaaks, Renée Turzanski Fortner, Anika Hüsing, Myrto Barrdahl, Marika Hopper, Theron Johnson, Anne Tjønneland, Louise Hansen, Kim Overvad, Agnès Fournier, Marie‐Christine Boutron‐Ruault, Marina Kvaskoff, Laure Dossus, Mattias Johansson, Heiner Boeing, Antonia Trichopoulou, Vassiliki Benetou, Carlo La Vecchia, Sabina Sieri, Amalia Mattiello, Domenico Palli, Rosario Tumino, Giuseppe Matullo, N. Charlotte Onland‐Moret, Inger T. Gram, Elisabete Weiderpass, Maria‐Jose Sánchez, Carmen Navarro Sanchez, Eric J. Duell, Eva Ardanaz, Nerea Larranaga, Eva Lundin, Annika Idahl, Karin Jirström, Björn Nodin, Ruth C. Travis, Elio Riboli, Melissa Merritt, Dagfinn Aune, Kathryn Terry, Daniel W. Cramer, Karen S. Anderson |
| Abstract |
Immuno-proteomic screening has identified several tumor-associated auto-antibodies (AAb) that may have diagnostic capacity for invasive epithelial ovarian cancer, with AAbs to P53 proteins and cancer-testis antigens (CTAGs) as prominent examples. However, the early detection potential of these AAbs has been insufficiently explored in prospective studies. We performed ELISA measurements of AAbs to CTAG1A, CTAG2, P53, and NUDT11 proteins, for 194 patients with ovarian cancer and 705 matched controls from the European EPIC cohort, using serum samples collected up to 36 months prior to diagnosis under usual care. CA125 was measured using electrochemo-luminiscence. Diagnostic discrimination statistics were calculated by strata of lead-time between blood collection and diagnosis. With lead times ≤6 months, ovarian cancer detection sensitivity at 0.98 specificity (SE98) varied from 0.19 [95% CI 0.08-0.40] for CTAG1A, CTAG2 and NUDT1 to 0.23 [0.10-0.44] for P53 (0.33 [0.11-0.68] for high-grade serous tumors). However, at longer lead-times the ability of these AAb markers to distinguish future ovarian cancer cases from controls declined rapidly; at lead times >1 year, SE98 estimates were close to zero (all invasive cases, range: 0.01-0.11). Compared to CA125 alone, combined logistic regression scores of AAbs and CA125 did not improve detection sensitivity at equal level of specificity. The added value of these selected AAbs as markers for ovarian cancer beyond CA125 for early detection is therefore limited. This article is protected by copyright. All rights reserved. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 5 | 56% |
| United States | 1 | 11% |
| United Kingdom | 1 | 11% |
| Unknown | 2 | 22% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 89% |
| Scientists | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 42 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 14% |
| Student > Master | 5 | 12% |
| Researcher | 5 | 12% |
| Professor > Associate Professor | 3 | 7% |
| Student > Ph. D. Student | 3 | 7% |
| Other | 5 | 12% |
| Unknown | 15 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 33% |
| Biochemistry, Genetics and Molecular Biology | 4 | 10% |
| Agricultural and Biological Sciences | 3 | 7% |
| Social Sciences | 2 | 5% |
| Nursing and Health Professions | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 15 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 August 2019.
All research outputs
#6,819,949
of 25,311,095 outputs
Outputs from International Journal of Cancer
#4,310
of 12,261 outputs
Outputs of similar age
#109,623
of 338,952 outputs
Outputs of similar age from International Journal of Cancer
#41
of 130 outputs
Altmetric has tracked 25,311,095 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 12,261 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.1. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,952 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 130 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.